
  
    
      
        Introduction_NNP
        The_DT protective_JJ effects_NNS of_IN antibody_NN to_TO pneumococcal_NN capsular_NN polysaccharides_NNS have_VBP been_VBN
        appreciated_VBN since_IN the_DT development_NN of_IN serum_NN therapy_NN ,_, in_IN which_WDT passively_RB transferred_VBN ,_,
        serotype-specific_JJ antipneumococcal_NN serum_NN reduced_VBD mortality_NN from_IN pneumococcal_NN pneumonia_NN by_IN
        half_JJ [_NN 1_CD ]_NN ._. The_DT development_NN of_IN pneumococcal_NN polysaccharide_NN vaccines_NNS for_IN adults_NNS [_NN 2_CD ]_NN and_CC the_DT
        efficacy_NN of_IN pneumococcal_NN polysaccharide–protein_NN conjugate_NN vaccines_NNS in_IN infants_NNS and_CC children_NNS
        [_NN 3_CD ,_, 4_CD ]_NN have_VBP confirmed_VBN that_IN active_JJ immunity_NN to_TO the_DT polysaccharide_NN can_MD provide_VB excellent_JJ
        protection_NN against_IN invasive_JJ disease_NN from_IN pneumococci_NN of_IN the_DT same_JJ serotype_NN ,_, and_CC in_IN some_DT
        cases_NNS protection_NN against_IN cross-reacting_JJ serotypes_NNS within_IN the_DT same_JJ serogroup_NN ._.
        While_IN the_DT ability_NN of_IN passive_JJ or_CC vaccine-induced_JJ anticapsular_NN antibodies_NNS to_TO protect_VB
        against_IN pneumococcal_NN disease_NN is_VBZ clear_JJ ,_, less_JJR is_VBZ known_VBN about_IN the_DT natural_JJ development_NN of_IN
        immunity_NN to_TO pneumococcal_NN disease_NN in_IN unimmunized_JJ persons_NNS ._. In_IN unimmunized_JJ populations_NNS ,_, the_DT
        incidence_NN of_IN invasive_JJ disease_NN follows_VBZ a_DT well-known_JJ age_NN distribution_NN ,_, peaking_VBG in_IN the_DT first_JJ 2_CD
        y_NN of_IN life_NN ,_, declining_VBG by_IN more_JJR than_IN an_DT order_NN of_IN magnitude_NN by_IN the_DT second_JJ and_CC third_JJ decades_NNS of_IN
        life_NN ,_, and_CC then_RB rising_VBG at_IN an_DT accelerating_VBG pace_NN ,_, with_IN incidence_NN in_IN persons_NNS over_IN 70_CD y_NN
        approaching_VBG that_IN in_IN infants_NNS [_NN 5_CD ]_NN ._. The_DT reason_NN for_IN the_DT decline_NN in_IN incidence_NN has_VBZ not_RB been_VBN
        conclusively_RB determined_VBN ,_, yet_RB it_PRP is_VBZ often_RB suggested_VBN that_IN the_DT acquisition_NN of_IN anticapsular_NN
        antibodies_NNS plays_VBZ a_DT critical_JJ role_NN in_IN this_DT decline_NN [_NN 6_CD ,_, 7_CD ]_NN ._. Indeed_RB ,_, it_PRP has_VBZ been_VBN proposed_VBN that_IN
        the_DT human_JJ immune_JJ system_NN sees_VBZ each_DT serotype_NN of_IN 
        Streptococcus_NNP pneumoniae_NN as_IN a_DT distinct_JJ ,_, independent_JJ pathogen_NN
        [_NN 8_CD ]_NN ._.
        The_DT hypothesis_NNS that_WDT protection_NN from_IN invasive_JJ pneumococcal_NN disease_NN is_VBZ caused_VBN by_IN the_DT
        acquisition_NN of_IN anticapsular_NN antibodies_NNS directed_VBN against_IN each_DT of_IN the_DT pneumococcal_NN serotypes_NNS
        yields_NNS two_CD simple_JJ predictions_NNS about_IN the_DT age-specific_JJ epidemiology_NN of_IN pneumococcal_NN disease_NN ._.
        First_LS ,_, it_PRP predicts_VBZ that_IN the_DT age-specific_JJ timing_NN of_IN the_DT decline_NN in_IN invasive_JJ disease_NN should_MD
        be_VB different_JJ for_IN different_JJ serotypes_NNS :_: those_DT that_WDT are_VBP rare_JJ ,_, poorly_RB immunogenic_JJ ,_, or_CC both_DT
        should_MD decline_VB later_RB in_IN life_NN than_IN those_DT that_WDT are_VBP common_JJ and_CC immunogenic_JJ ._. Second_JJ ,_, it_PRP
        predicts_VBZ that_DT protection_NN against_IN invasive_JJ disease_NN from_IN a_DT given_VBN serotype_NN should_MD coincide_VB
        temporally_RB with_IN the_DT acquisition_NN of_IN anticapsular_NN antibody_NN to_TO that_DT serotype_NN ,_, both_DT at_IN an_DT
        individual_JJ level_NN and_CC at_IN a_DT population_NN level_NN ._. We_PRP tested_VBD these_DT predictions_NNS using_VBG data_NNS from_IN the_DT
        United_NNP States_NNPS ,_, Finland_NNP ,_, and_CC Israel_NNP ._.
      
      
        Methods_NNP
        
          United_NNP States_NNPS Dataset_NNP
          Incidence_NNP of_IN invasive_JJ pneumococcal_NN disease_NN was_VBD measured_VBN in_IN eight_CD sites_NNS around_IN the_DT
          United_NNP States_NNPS participating_VBG in_IN the_DT Centers_NNPS for_IN Disease_NNP Control_NNP and_CC Prevention_NNP 's_POS Active_JJ
          Bacterial_NNP Core_NNP Surveillance_NNP between_IN 1994_CD and_CC 1999_CD ._. The_DT data_NNS used_VBN here_RB are_VBP restricted_VBN to_TO
          those_DT periods_NNS during_IN which_WDT serotyping_VBG was_VBD routinely_RB performed_VBN :_: 1994_CD –_NN 1999_CD for_IN the_DT Georgia_NNP
          site_NN ,_, 1995_CD –_NN 1999_CD for_IN the_DT Minnesota_NNP site_NN ,_, and_CC 1998_CD –_NN 1999_CD for_IN all_DT other_JJ sites_NNS [_NN 5_CD ]_NN ._. Data_NNP were_VBD
          not_RB available_JJ on_IN the_DT timing_NN of_IN anticapsular_NN antibody_NN acquisition_NN in_IN these_DT same_JJ
          populations_NNS ,_, but_CC we_PRP compared_VBD the_DT timing_NN of_IN the_DT decline_NN in_IN pneumococcal_NN disease_NN against_IN
          previously_RB published_VBN data_NNS on_IN age-specific_JJ prevalence_NN of_IN anticapsular_NN antibody_NN levels_NNS
          greater_JJR than_IN 0_CD ._. 2_CD mcg_NN /_NN ml_NN [_NN 9_CD ]_NN ._.
        
        
          Israel_NNP Dataset_NNP
          Antibody_NNP concentrations_NNS were_VBD measured_VBN by_IN enzyme-linked_JJ immunosorbent_NN assay_NN (_( ELISA_NNP )_)
          (_( with_IN absorption_NN by_IN cell_NN wall_NN polysaccharide_NN but_CC not_RB by_IN 22_CD F_NN polysaccharide_NN )_) in_IN blood_NN
          samples_NNS that_WDT were_VBD obtained_VBN from_IN 130_CD toddlers_NNS at_IN enrollment_NN and_CC at_IN approximately_RB 12_CD and_CC 24_CD
          mo_NN after_IN enrollment_NN in_IN a_DT double-blind_JJ ,_, controlled_VBN trial_NN of_IN a_DT nine-valent_JJ pneumococcal_NN
          conjugate_NN vaccine_NN ._. The_DT toddlers_NNS analyzed_VBD for_IN this_DT study_NN were_VBD those_DT in_IN the_DT control_NN group_NN ,_,
          which_WDT received_VBD meningococcal_NN C_NNP conjugate_NN vaccine_NN ;_: the_DT details_NNS of_IN the_DT trial_NN [_NN 10_CD ]_NN were_VBD
          previously_RB described_VBN ._. Preliminary_JJ analyses_NNS of_IN these_DT data_NNS confirmed_VBD previous_JJ findings_NNS [_NN 11_CD ]_NN
          that_IN ELISA_NNP measurements_NNS were_VBD highly_RB correlated_JJ (_( and_CC therefore_RB likely_RB revealed_VBD
          cross-reactions_JJ )_) for_IN all_DT pairs_NNS of_IN serotypes_NNS ,_, except_IN for_IN type_NN 14_CD ,_, for_IN which_WDT correlations_NNS
          were_VBD minimal_JJ ,_, consistent_JJ with_IN previous_JJ findings_NNS of_IN little_RB cross-reaction_JJ ._. For_IN this_DT
          reason_NN ,_, we_PRP chose_VBD to_TO analyze_VB age_NN trends_NNS only_RB in_IN serotype_NN 14_CD antibodies_NNS ._.
        
        
          Finland_NNP Dataset_NNP
          Mandatory_NNP reporting_VBG from_IN all_DT microbiological_JJ laboratories_NNS in_IN Finland_NNP to_TO the_DT National_NNP
          Register_NNP of_IN Infectious_NNP Disease_NNP (_( http_NN :_: /_NN /_NN www_NN 3_CD ._. ktl_NN ._. fi_NN /_NN stat_NN /_NN )_) identified_VBD all_DT blood_NN and_CC
          cerebrospinal_NN fluid_JJ isolates_VBZ of_IN 
          S_NNP ._. pneumoniae_NN obtained_VBN in_IN the_DT years_NNS 1995_CD –_NN 2001_CD ._. Incidence_NNP
          within_IN 6_CD -_: mo_NN age_NN groups_NNS was_VBD calculated_VBN using_VBG population_NN denominators_NNS obtained_VBN from_IN
          Statistics_NNPS Finland_NNP (_( Helsinki_NNP ,_, Finland_NNP )_) ._. Since_IN the_DT primary_JJ purpose_NN of_IN examining_VBG incidence_NN
          in_IN Finland_NNP was_VBD to_TO compare_VB age-specific_JJ rates_NNS against_IN published_VBN distributions_NNS of_IN antibody_NN
          concentrations_NNS for_IN the_DT same_JJ age_NN groups_NNS [_NN 12_CD ]_NN ,_, we_PRP restricted_VBD our_PRP$ attention_NN to_TO serotype_NN 14_CD
          and_CC serogroup_NN 6_CD ,_, for_IN which_WDT subsequent_JJ investigations_NNS suggested_VBD antibody_NN measurements_NNS in_IN
          Finland_NNP were_VBD relatively_RB unaffected_JJ by_IN cross-reactions_JJ [_NN 13_CD ]_NN (_( ELISA_NNP measurements_NNS for_IN
          published_VBN data_NNS from_IN Finland_NNP used_VBD a_DT special_JJ type_NN 6_CD B_NNP polysaccharide_NN that_WDT was_VBD found_VBN to_TO
          minimize_VB cross-reactions_JJ [_NN 13_CD ]_NN )_) ._.
        
      
      
        Results_NNS
        
          United_NNP States_NNPS Findings_NNP
          Figure_NN 1_CD shows_VBZ the_DT age-specific_JJ incidence_NN of_IN invasive_JJ pneumococcal_NN disease_NN ,_, by_IN
          capsular_NN serogroup_NN ,_, obtained_VBN from_IN population-based_JJ active_JJ surveillance_NN in_IN the_DT United_NNP
          States_NNPS prior_RB to_TO the_DT introduction_NN of_IN the_DT conjugate_NN vaccine_NN ._. Figure_NN 2_CD shows_VBZ age-specific_JJ
          incidence_NN by_IN type_NN of_IN infection_NN ,_, for_IN the_DT same_JJ age_NN range_NN ._.
          Incidence_NNP peaks_NNS between_IN the_DT ages_NNS of_IN 9_CD and_CC 15_CD mo_NN ,_, and_CC falls_VBZ in_IN an_DT approximately_RB
          parallel_JJ fashion_NN thereafter_RB ,_, for_IN each_DT of_IN the_DT seven_CD most_RBS important_JJ serogroups_NNS (_( which_WDT are_VBP
          those_DT included_VBN in_IN the_DT seven-valent_JJ conjugate_NN vaccine_NN )_) and_CC for_IN the_DT remaining_VBG serogroups_NNS
          put_VBP together_RB ._. The_DT same_JJ pattern_NN is_VBZ observed_VBN for_IN both_DT pneumonia_NN and_CC bacteremia_NN ._. For_IN each_DT
          serogroup_NN ,_, incidence_NN by_IN age_NN 24_CD mo_NN is_VBZ approximately_RB half_NN that_IN in_IN the_DT peak_NN age_NN group_NN ,_, and_CC
          by_IN 36_CD mo_NN ,_, incidence_NN for_IN each_DT serogroup_NN has_VBZ fallen_VBN to_TO 10_CD %_NN –_NN 25_CD %_NN of_IN its_PRP$ peak_NN ._.
          The_DT consistent_JJ timing_NN of_IN the_DT pattern_NN across_IN multiple_JJ serogroups_NNS argues_VBZ for_IN a_DT common_JJ
          mechanism_NN ,_, rather_RB than_IN for_IN independent_JJ acquisition_NN of_IN immunity_NN to_TO each_DT serogroup_NN as_IN a_DT
          separate_JJ event_NN ._. Since_IN most_JJS individuals_NNS do_VBP not_RB suffer_VB from_IN invasive_JJ pneumococcal_NN disease_NN
          in_IN this_DT age_NN range_NN ,_, carriage_NN or_CC mucosal_NN disease_NN (_( otitis_NNS media_NNS )_) from_IN pneumococci_NN may_MD be_VB the_DT
          immunizing_VBG event_NN for_IN anticapsular_NN antibodies_NNS in_IN the_DT general_JJ population_NN [_NN 12_CD ]_NN (_( although_IN in_IN
          principle_NN immunity_NN to_TO some_DT serogroups_NNS could_MD be_VB generated_VBN in_IN response_NN to_TO cross-reacting_JJ
          antigens_NNS from_IN other_JJ bacterial_JJ species_NNS or_CC other_JJ sources_NNS [_NN 14_CD ]_NN )_) ._. Different_JJ serogroups_NNS have_VBP
          vastly_RB different_JJ frequencies_NNS among_IN pneumococci_NN isolated_VBN from_IN carriage_NN [_NN 12_CD ,_, 15_CD ,_, 16_CD ,_, 17_CD ]_NN and_CC
          otitis_NNS media_NNS [_NN 12_CD ,_, 18_CD ]_NN ;_: for_IN example_NN ,_, serogroups_NNS 4_CD and_CC 18_CD and_CC the_DT non-vaccine_JJ serogroups_NNS are_VBP
          isolated_VBN far_RB less_RBR commonly_RB than_IN several_JJ of_IN the_DT other_JJ pneumococcal_NN types_NNS identified_VBN in_IN
          Figure_NN 1_CD ._. One_PRP could_MD postulate_NN that_IN these_DT differences_NNS in_IN frequency_NN of_IN carriage_NN are_VBP offset_VBN
          by_IN differences_NNS in_IN immunogenicity_NN ;_: however_RB ,_, there_EX is_VBZ little_JJ evidence_NN that_IN serotypes_NNS 4_CD or_CC
          18_CD C_NNP are_VBP more_RBR immunogenic_JJ than_IN other_JJ ,_, far_RB more_RBR common_JJ serotypes_NNS [_NN 4_CD ,_, 15_CD ]_NN ._. One_PRP could_MD also_RB
          postulate_NN that_IN the_DT frequency_NN of_IN isolation_NN of_IN serotypes_NNS from_IN carriage_NN depends_VBZ on_IN duration_NN
          as_RB well_RB as_IN incidence_NN ,_, so_IN that_IN the_DT serotypes_NNS for_IN which_WDT carriage_NN appears_VBZ rare_JJ are_VBP simply_RB
          carried_VBN for_IN a_DT shorter_JJR duration_NN ._. While_IN the_DT data_NNS to_TO address_VB this_DT speculation_NN are_VBP limited_JJ ,_,
          the_DT duration_NN of_IN carriage_NN of_IN types_NNS 4_CD and_CC 18_CD C_NNP seems_VBZ to_TO be_VB comparable_JJ to_TO that_DT of_IN other_JJ ,_, more_RBR
          frequently_RB carried_VBD serotypes_NNS [_NN 15_CD ,_, 16_CD ]_NN ._. Thus_RB ,_, the_DT most_RBS parsimonious_JJ interpretation_NN of_IN the_DT
          data_NNS on_IN the_DT timing_NN of_IN the_DT decline_NN in_IN age-specific_JJ susceptibility_NN is_VBZ that_IN one_CD or_CC more_RBR
          common_JJ mechanisms_NNS are_VBP responsible_JJ for_IN the_DT decline_NN in_IN disease_NN from_IN all_DT serotypes_NNS ._.
          Testing_NNP the_DT second_JJ prediction_NN against_IN data_NNS is_VBZ hampered_VBN by_IN the_DT fact_NN that_IN ,_, to_TO our_PRP$
          knowledge_NN ,_, no_DT study_NN has_VBZ characterized_VBN the_DT age-specific_JJ distribution_NN of_IN antibody_NN
          concentration_NN in_IN a_DT large_JJ population_NN using_VBG the_DT currently_RB accepted_VBN methodology_NN ,_, which_WDT
          includes_VBZ absorption_NN with_IN both_DT cell_NN wall_NN polysaccharide_NN and_CC serotype_NN 22_CD F_NN polysaccharide_NN
          [_NN 13_CD ,_, 19_CD ]_NN ._. Analyses_NNS by_IN Soininen_NNP and_CC colleagues_NNS have_VBP found_VBN that_IN antibodies_NNS measured_VBN by_IN
          standard_JJ ELISA_NNP in_IN unimmunized_JJ children_NNS are_VBP highly_RB cross-reactive_JJ between_IN different_JJ
          serotypes_NNS ,_, and_CC that_IN cross-reactive_JJ antibodies_NNS lack_VBP opsonophagocytic_JJ function_NN and_CC often_RB
          appear_VB in_IN the_DT absence_NN of_IN any_DT documented_VBN exposure_NN to_TO a_DT given_VBN capsular_NN serotype_NN ._. As_IN a_DT
          result_NN ,_, age-specific_JJ antibody_NN concentration_NN data_NNS for_IN any_DT given_VBN serotype_NN are_VBP
          “ contaminated_JJ ,_,” to_TO a_DT greater_JJR or_CC lesser_JJR degree_NN ,_, by_IN cross-reactive_JJ antibodies_NNS with_IN other_JJ
          specificties_NNS ._.
          The_DT most_RBS important_JJ exception_NN to_TO this_DT problem_NN occurs_VBZ for_IN antibodies_NNS to_TO serotype_NN 14_CD ,_, for_IN
          which_WDT cross-reaction_JJ is_VBZ minimal_JJ [_NN 11_CD ]_NN ._. A_DT recent_JJ publication_NN describes_VBZ the_DT age-specific_JJ
          proportion_NN of_IN children_NNS in_IN the_DT United_NNP States_NNPS with_IN anti-type-_JJ 14_CD polysaccharide_NN antibody_NN
          concentration_NN exceeding_VBG the_DT putative_JJ protective_JJ concentration_NN of_IN 0_CD ._. 2_CD μg_NN /_NN ml_NN (_( Figure_NN 3_CD of_IN
          [_NN 9_CD ]_NN )_) ._. At_IN 12_CD mo_NN ,_, 90_CD %_NN –_NN 95_CD %_NN of_IN the_DT population_NN falls_VBZ below_IN this_DT level_NN ,_, and_CC at_IN 24_CD mo_NN ,_, 80_CD %_NN –_NN 85_CD %_NN
          remains_VBZ below_IN it—despite_NN a_DT 40_CD %_NN –_NN 50_CD %_NN drop_NN in_IN disease_NN incidence_NN from_IN 12_CD mo_NN to_TO 24_CD mo_NN ._. At_IN 36_CD
          mo_NN ,_, 75_CD %_NN of_IN children_NNS remain_VBP below_IN the_DT putative_JJ protective_JJ level_NN ,_, although_IN by_IN this_DT age_NN
          incidence_NN has_VBZ fallen_VBN more_JJR than_IN 80_CD %_NN from_IN its_PRP$ 12_CD -_: mo_NN peak_NN ._. In_IN summary_NN ,_, if_IN the_DT 0_CD ._. 2_CD -_: μg_NN /_NN ml_NN
          concentration_NN were_VBD truly_RB the_DT threshold_NN for_IN “ protection_NN ,_,” the_DT 20_CD %_NN –_NN 30_CD %_NN reduction_NN in_IN the_DT
          unprotected_JJ population_NN between_IN ages_NNS 12_CD and_CC 36_CD mo_NN would_MD be_VB inadequate_JJ to_TO explain_VB the_DT 90_CD %_NN
          decline_NN in_IN disease_NN incidence_NN ._. Clearly_RB ,_, 0_CD ._. 2_CD μg_NN /_NN ml_NN is_VBZ not_RB a_DT precise_JJ dividing_VBG line_NN between_IN
          being_VBG “ protected_VBN” and_CC “ unprotected_JJ ,_,” a_DT threshold_NN that_IN (_( if_IN it_PRP exists_VBZ )_) may_MD vary_VB by_IN
          serotype_NN ,_, but_CC given_VBN the_DT available_JJ data_NN ,_, there_EX is_VBZ reason_NN to_TO doubt_VB that_IN anti-type-_JJ 14_CD
          antibody_NN alone_RB is_VBZ responsible_JJ for_IN the_DT decline_NN in_IN disease_NN in_IN this_DT age_NN range_NN ._.
        
        
          Israel_NNP Findings_NNP
          To_TO assess_VB whether_IN the_DT limitations_NNS of_IN the_DT United_NNP States_NNPS antibody_NN described_VBD above—i_NN ._. e_SYM ._. ,_,
          the_DT availability_NN of_IN only_RB one_CD cutoff_NN point_NN for_IN antibody_NN concentrations—might_NN be_VB providing_VBG
          an_DT incomplete_JJ picture_NN of_IN the_DT distribution_NN of_IN antibody_NN levels_NNS by_IN age_NN ,_, we_PRP examined_VBD an_DT
          additional_JJ dataset_NN from_IN Israeli_JJ toddlers_NNS ._. For_IN the_DT reasons_NNS described_VBD above_IN ,_, we_PRP examined_VBD
          only_RB antibodies_NNS to_TO serotype_NN 14_CD ,_, for_IN which_WDT the_DT distribution_NN of_IN concentrations_NNS by_IN age_NN is_VBZ
          shown_VBN in_IN Figure_NN 3_CD ._. These_DT data_NNS indicate_VBP that_IN between_IN the_DT ages_NNS of_IN 12_CD –_NN 17_CD and_CC 36_CD –_NN 41_CD mo_NN ,_, the_DT
          median_JJ antibody_NN concentration_NN increases_NNS by_IN about_IN 2_CD -_: fold_VB ._. These_DT data_NNS are_VBP broadly_RB
          consistent_JJ with_IN those_DT published_VBN for_IN the_DT United_NNP States_NNPS ;_: antibody_NN levels_NNS rise_VBP very_RB
          gradually_RB ,_, though_IN detectably_RB ,_, during_IN the_DT second_JJ and_CC third_JJ years_NNS of_IN life_NN ._. It_PRP is_VBZ difficult_JJ
          to_TO believe—albeit_NN not_RB impossible—that_NN the_DT dramatic_JJ declines_NNS in_IN disease_NN incidence_NN over_IN
          these_DT years_NNS are_VBP explained_VBN simply_RB by_IN this_DT small_JJ rise_NN in_IN antibody_NN concentrations_NNS ._.
        
        
          Finland_NNP Findings_NNP
          Incidence_NNP of_IN serogroup_NN 6_CD and_CC serotype_NN 14_CD invasive_JJ pneumococcal_NN disease_NN by_IN 6_CD -_: mo_NN age_NN
          groups_NNS in_IN Finland_NNP ,_, shown_VBN in_IN Figure_NN 4_CD ,_, is_VBZ broadly_RB similar_JJ to_TO that_DT found_VBD in_IN the_DT United_NNP
          States_NNPS ,_, albeit_IN with_IN lower_JJR absolute_JJ incidence_NN for_IN both_DT serogroups_NNS ._. Peak_NNP incidence_NN occurs_VBZ
          in_IN the_DT 12_CD –_NN 17_CD -_: mo_NN age_NN group_NN ,_, and_CC incidence_NN declines_NNS to_TO 25_CD %_NN –_NN 30_CD %_NN of_IN its_PRP$ peak_NN rate_NN by_IN 24_CD –_NN 29_CD mo_NN
          of_IN age_NN ._. This_DT decline_NN in_IN incidence_NN may_MD be_VB compared_VBN against_IN the_DT cumulative_JJ distributions_NNS of_IN
          antibody_NN concentrations_NNS in_IN Finnish_JJ toddlers_NNS shown_VBN in_IN Figure_NN 2_CD of_IN [_NN 12_CD ]_NN ._. Between_IN ages_NNS 12_CD
          and_CC 24_CD mo_NN ,_, there_EX is_VBZ a_DT discernible_JJ increase_NN in_IN the_DT concentration_NN of_IN antibodies_NNS in_IN the_DT
          population_NN ,_, but_CC the_DT median_JJ concentration_NN increases_NNS by_IN only_RB about_IN 2_CD -_: fold_VB in_IN this_DT period_NN ._.
          Moreover_RB ,_, the_DT proportion_NN of_IN the_DT population_NN with_IN antibody_NN concentration_NN below_IN any_DT
          particular_JJ threshold_NN that_WDT may_MD indicate_VB protection_NN changes_NNS little_JJ in_IN this_DT period_NN ._. For_IN
          example_NN ,_, the_DT proportion_NN of_IN the_DT population_NN with_IN anti-type-_JJ 14_CD antibody_NN concentrations_NNS less_JJR
          than_IN 0_CD ._. 2_CD μg_NN /_NN ml_NN declines_NNS from_IN approximately_RB 55_CD %_NN to_TO approximately_RB 40_CD %_NN ,_, and_CC the_DT proportion_NN
          with_IN less_JJR than_IN 0_CD ._. 5_CD μg_NN /_NN ml_NN is_VBZ reduced_VBN from_IN about_IN 95_CD %_NN to_TO about_IN 80_CD %_NN ._. Similar_JJ patterns_NNS are_VBP
          seen_VBN in_IN the_DT Finnish_JJ antibody_NN data_NNS for_IN type_NN 6_CD B_NNP [_NN 12_CD ]_NN ._. Thus_RB ,_, as_IN in_IN the_DT Israeli_JJ data_NN ,_, only_RB a_DT
          very_RB small_JJ shift_NN in_IN the_DT distribution_NN of_IN type-specific_JJ anti-polysaccharide_JJ antibody_NN
          concentration_NN is_VBZ observed_VBN during_IN the_DT second_JJ year_NN of_IN life_NN ,_, yet_RB incidence_NN of_IN invasive_JJ
          disease_NN from_IN the_DT serotypes_NNS in_IN question_NN declines_NNS substantially_RB ._.
        
      
      
        Discussion_NNP
        We_PRP have_VBP assessed_VBN two_CD lines_NNS of_IN epidemiological_JJ evidence_NN ,_, analyzed_VBD ecologically_RB ,_, that_DT bear_NN
        on_IN the_DT role_NN of_IN anticapsular_NN polysaccharide_NN antibody_NN as_IN the_DT determinant_NN of_IN protection_NN
        against_IN invasive_JJ disease_NN that_WDT develops_VBZ during_IN the_DT second_JJ and_CC third_JJ year_NN of_IN life_NN ._. The_DT
        simultaneous_JJ and_CC approximately_RB parallel_JJ nature_NN of_IN the_DT decline_NN in_IN disease_NN incidence_NN for_IN the_DT
        seven_CD most_RBS important_JJ serogroups_NNS in_IN the_DT United_NNP States_NNPS suggests_VBZ that_IN one_CD mechanism_NN ,_, rather_RB
        than_IN seven_CD independent_JJ mechanisms_NNS ,_, account_NN for_IN the_DT declines_NNS in_IN invasive_JJ disease_NN from_IN these_DT
        serogroups_NNS ._. Moreover_RB ,_, only_RB a_DT slight_JJ increase_NN in_IN anticapsular_NN antibody_NN concentration_NN is_VBZ
        measurable_JJ in_IN Finnish_JJ ,_, United_NNP States_NNPS ,_, and_CC Israeli_JJ toddlers_NNS during_IN the_DT same_JJ age_NN range_NN ._. As_IN we_PRP
        discuss_VBP below_RB ,_, each_DT of_IN these_DT lines_NNS of_IN evidence_NN is_VBZ subject_JJ to_TO caveats_NNS ,_, but_CC we_PRP believe_VBP that_IN ,_,
        taken_VBN together_RB ,_, these_DT observations_NNS make_VBP a_DT strong_JJ case_NN for_IN the_DT importance_NN of_IN one_CD or_CC more_JJR
        factors_NNS other_JJ than_IN acquisition_NN of_IN anticapsular_NN antibodies_NNS in_IN the_DT development_NN of_IN protection_NN
        against_IN pneumococcal_NN disease_NN ._.
        There_EX are_VBP several_JJ possible_JJ candidates_NNS for_IN mechanisms_NNS that_WDT could_MD explain_VB this_DT age-related_JJ
        decline_NN in_IN pneumococcal_NN disease_NN ._. These_DT include_VBP the_DT following_VBG :_: acquisition_NN of_IN antibodies_NNS or_CC
        cellular_JJ immune_JJ responses_NNS to_TO noncapsular_NN pneumococcal_NN “ species_NNS” antigens_NNS ;_: age-related_JJ
        changes_NNS in_IN host_NN biology_NN that_WDT are_VBP not_RB related_VBN to_TO acquired_VBN immunity_NN ,_, such_JJ as_IN maturation_NN of_IN
        the_DT innate_JJ immune_JJ system_NN or_CC changes_NNS in_IN anatomy_NN or_CC receptors_NNS for_IN pneumococcal_NN attachment_NN ;_:
        changes_NNS in_IN other_JJ risk_NN factors_NNS ,_, such_JJ as_IN exposure_NN ;_: or_CC changes_NNS related_VBN to_TO other_JJ
        microorganisms_NNS ,_, including_VBG changes_NNS in_IN the_DT resident_NN flora_NNS or_CC changes_NNS in_IN the_DT incidence_NN of_IN
        viral_JJ infections_NNS ._.
        Systemic_NNP antibodies_NNS to_TO several_JJ pneumococcal_NN protein_NN antigens_NNS ,_, which_WDT are_VBP conserved_JJ across_IN
        pneumococcal_NN strains_NNS and_CC serotypes_NNS ,_, develop_VB following_VBG pneumococcal_NN carriage_NN and_CC otitis_NNS
        media_NNS and_CC are_VBP present_JJ by_IN the_DT beginning_NN of_IN the_DT second_JJ year_NN of_IN life_NN [_NN 20_CD ,_, 21_CD ]_NN ._. In_IN both_DT Finland_NNP
        [_NN 20_CD ]_NN and_CC Kenya_NNP [_NN 21_CD ]_NN ,_, there_EX is_VBZ an_DT increase_NN in_IN the_DT concentration_NN of_IN antibodies_NNS to_TO the_DT
        pneumococcal_NN proteins_NNS pneumolysin_NN and_CC pneumococcal_NN surface_NN protein_NN A_DT over_IN the_DT first_JJ two_CD or_CC
        more_JJR years_NNS of_IN life_NN ._. In_IN Kenya_NNP ,_, antibodies_NNS to_TO another_DT conserved_JJ protein_NN ,_, pneumococcal_NN surface_NN
        adhesin_NN A_DT ,_, showed_VBD similar_JJ distributions_NNS in_IN the_DT first_JJ ,_, second_JJ ,_, and_CC subsequent_JJ years_NNS of_IN life_NN ,_,
        while_IN in_IN Finland_NNP ,_, levels_NNS of_IN these_DT antibodies_NNS were_VBD already_RB high_JJ (_( equivalent_JJ to_TO adult_NN levels_NNS )_)
        in_IN the_DT first_JJ year_NN of_IN life_NN ,_, and_CC increased_VBD above_IN these_DT levels_NNS in_IN the_DT second_JJ year_NN ._. In_IN mice_NNS ,_,
        either_CC passively_RB transferred_VBN human_JJ serum_NN IgG_NNP against_IN pneumococcal_NN surface_NN protein_NN A_DT or_CC
        vaccine-induced_JJ antibodies_NNS to_TO pneumococcal_NN surface_NN protein_NN A_DT and_CC /_NN or_CC pneumolysin_NN are_VBP
        protective_JJ against_IN invasive_JJ disease_NN ._. Such_JJ data_NNS are_VBP consistent_JJ with_IN the_DT hypothesis_NNS that_IN
        antibodies_NNS to_TO these_DT ,_, or_CC perhaps_RB other_JJ ,_, conserved_JJ pneumococcal_NN proteins_NNS are_VBP in_IN part_NN
        responsible_JJ for_IN the_DT decline_NN in_IN invasive_JJ disease_NN in_IN the_DT second_JJ and_CC subsequent_JJ years_NNS of_IN
        life_NN ._.
        A_DT number_NN of_IN investigators_NNS have_VBP tested_VBN the_DT hypothesis_NNS that_IN antibodies_NNS to_TO the_DT pneumococcal_NN
        teichoic_JJ acid_NN ,_, known_VBN as_IN cell_NN wall_NN polysaccharide_NN (_( CWPS_NNP )_) ,_, are_VBP capable_JJ of_IN protecting_VBG
        individuals_NNS against_IN pneumococcal_NN invasive_JJ disease_NN ._. While_IN studies_NNS in_IN animals_NNS [_NN 22_CD ]_NN and_CC humans_NNS
        [_NN 23_CD ]_NN have_VBP failed_VBN to_TO find_VB a_DT protective_JJ effect_NN of_IN antibodies_NNS to_TO CWPS_NNP or_CC its_PRP$ components_NNS ,_, a_DT
        recent_JJ study_NN showed_VBD that_IN passive_JJ transfer_NN of_IN human_JJ IgG_NNP against_IN phosphorylcholine_NN ,_, a_DT
        component_NN of_IN CWPS_NNP ,_, could_MD protect_VB mice_NNS against_IN invasive_JJ pneumococcal_NN infections_NNS [_NN 24_CD ]_NN ._.
        Notably_RB ,_, such_JJ antibodies_NNS might_MD be_VB elicited_JJ by_IN a_DT number_NN of_IN bacteria_NNS in_IN addition_NN to_TO
        pneumococci_NN ,_, such_JJ as_IN 
        Haemophilus_NNP influenzae_NN ,_, which_WDT also_RB produce_VB phosphorylcholine_NN ._. We_PRP are_VBP
        unaware_JJ of_IN studies_NNS on_IN the_DT timing_NN of_IN acquisition_NN of_IN anti-_NN CWPS_NNP antibodies_NNS ._.
        We_PRP have_VBP recently_RB shown_VBN that_IN mice_NNS that_WDT are_VBP exposed_VBN thrice_NN at_IN weekly_JJ intervals_NNS to_TO
        intranasal_NN colonization_NN with_IN encapsulated_JJ pneumococci_NN are_VBP protected_VBN against_IN subsequent_JJ
        carriage_NN ,_, that_IN this_DT protection_NN is_VBZ effective_JJ for_IN heterologous_JJ as_IN well_RB as_RB homologous_RB capsular_NN
        types_NNS ,_, and_CC that_IN it_PRP is_VBZ effective_JJ even_RB in_IN MuMT_NNP mice_NNS ,_, which_WDT lack_VBP the_DT ability_NN to_TO produce_VB
        antibodies_NNS (_( Malley_NNP R_NNP ,_, Trzcinski_NNP K_NNP ,_, Srivastava_NNP A_DT ,_, Thompson_NNP CM_NNP ,_, Anderson_NNP PW_NNP ,_, et_CC al_NN ._. ,_,
        unpublished_JJ data_NNS )_) ._. We_PRP have_VBP also_RB shown_VBN that_DT intranasal_NN immunization_NN with_IN unencapsulated_JJ ,_,
        killed_VBN pneumococci_NN protects_VBZ against_IN nasopharyngeal_NN colonization_NN ,_, in_IN a_DT fashion_NN that_WDT is_VBZ
        independent_JJ of_IN antibody_NN but_CC requires_VBZ CD_NNP 4_CD +_NN T_NN cells_NNS at_IN the_DT time_NN of_IN challenge_NN ._. The_DT relevance_NN
        of_IN cellular_JJ immune_JJ mechanisms_NNS in_IN protecting_VBG humans_NNS against_IN pneumococcal_NN colonization_NN or_CC
        disease_NN is_VBZ not_RB known_VBN ._.
        Another_DT candidate_NN for_IN a_DT factor_NN that_WDT may_MD be_VB changing_VBG with_IN age_NN is_VBZ susceptibility_NN to_TO viral_JJ
        infections_NNS ,_, especially_RB influenza_NN ,_, which_WDT may_MD predispose_VB to_TO pneumococcal_NN colonization_NN [_NN 25_CD ]_NN or_CC
        disease_NN [_NN 26_CD ,_, 27_CD ]_NN ._. Recent_JJ evidence_NN from_IN clinical_JJ trials_NNS of_IN pneumococcal_NN conjugate_NN vaccines_NNS
        shows_VBZ that_IN the_DT vaccines_NNS can_MD reduce_VB the_DT incidence_NN of_IN infections_NNS such_JJ as_IN bronchiolitis_NNS that_WDT
        are_VBP usually_RB associated_VBN with_IN viruses_NNS [_NN 28_CD ]_NN and_CC of_IN documented_VBN ,_, virus-associated_JJ pneumonia_NN
        [_NN 27_CD ]_NN ._. These_DT findings_NNS raise_VBP the_DT possibility_NN that_IN the_DT decline_NN in_IN pneumococcal_NN disease_NN with_IN
        age_NN reflects_VBZ ,_, in_IN part_NN ,_, a_DT decline_NN in_IN the_DT incidence_NN or_CC severity_NN of_IN viral_JJ infections_NNS ,_, so_IN that_IN
        fewer_RBR such_JJ infections_NNS lead_VBP to_TO secondary_JJ pneumococcal_NN disease_NN ._.
        Exposure_NNP to_TO pneumococci_NN probably_RB changes_VBZ in_IN some_DT fashion_NN over_IN the_DT first_JJ 5_CD y_NN of_IN life_NN ._.
        However_RB ,_, for_IN changes_NNS in_IN exposure_NN to_TO account_VB for_IN the_DT sharp_JJ drop_NN in_IN disease_NN incidence_NN
        following_VBG the_DT first_JJ birthday_NN ,_, it_PRP would_MD be_VB necessary_JJ for_IN exposure_NN also_RB to_TO drop_VB severalfold_NN
        per_IN year_NN over_IN this_DT age_NN range_NN ._. Studies_NNS of_IN pneumococcal_NN carriage_NN do_VBP show_VB gradual_JJ changes_NNS in_IN
        the_DT prevalence_NN and_CC serotype_NN composition_NN of_IN the_DT nasopharyngeal_NN flora_NNS in_IN these_DT years_NNS ,_, but_CC the_DT
        prevalence_NN of_IN carriage_NN changes_NNS much_RB more_RBR gradually_RB than_IN the_DT incidence_NN of_IN invasive_JJ disease_NN
        [_NN 29_CD ]_NN ._.
        We_PRP are_VBP not_RB aware_JJ of_IN data_NNS that_WDT bear_NN strongly_RB on_IN the_DT plausibility_NN of_IN other_JJ possible_JJ
        mechanisms_NNS for_IN the_DT age-related_JJ decline_NN in_IN pneumococcal_NN disease_NN ,_, such_JJ as_IN changes_NNS in_IN anatomy_NN ,_,
        physiology_NN ,_, receptor_NN expression_NN ,_, or_CC resident_NN bacterial_JJ flora_NNS ._. However_RB ,_, factors_NNS other_JJ than_IN
        antibody—such_NN as_IN innate_JJ or_CC acquired_VBN cellular_JJ immune_JJ responses_NNS ,_, age-related_JJ anatomical_JJ
        changes_NNS ,_, or_CC changes_NNS in_IN exposure_NN to_TO pneumococci—cannot_NN be_VB ruled_VBN out_IN ,_, and_CC more_JJR than_IN one_CD
        factor_NN may_MD be_VB involved_VBN ._. Indeed_RB ,_, the_DT peak_NN of_IN pneumococcal_NN meningitis_NNS incidence_NN in_IN the_DT 3_CD –_NN 6_CD -_: mo_NN
        age_NN group_NN (_( see_VB Figure_NN 2_LS )_) suggests_VBZ that_IN the_DT mechanism_NN of_IN protection_NN against_IN meningitis_NNS may_MD
        differ_VB from_IN those_DT against_IN pneumonia_NN and_CC bacteremia_NN ._.
        Although_IN we_PRP suggest_VBP that_DT anticapsular_NN antibody_NN is_VBZ not_RB primarily_RB responsible_JJ for_IN the_DT
        age-specific_JJ decline_NN in_IN invasive_JJ pneumococcal_NN disease_NN ,_, there_EX is_VBZ no_DT question_NN that_IN the_DT
        capsule_NN is_VBZ an_DT important_JJ virulence_NN factor_NN that_IN interacts_NNS with_IN the_DT innate_JJ and_CC acquired_VBN immune_JJ
        system_NN in_IN a_DT number_NN of_IN ways_NNS ._. It_PRP is_VBZ clear_JJ that_IN the_DT pneumococcal_NN capsule_NN interferes_VBZ with_IN
        various_JJ host_NN clearance_NN mechanisms_NNS [_NN 30_CD ]_NN ._. It_PRP would_MD be_VB unsurprising_JJ if_IN different_JJ capsular_NN
        types_NNS were_VBD differentially_RB effective_JJ in_IN permitting_VBG pneumococci_NN to_TO evade_VB phagocytosis_NNS and_CC
        other_JJ host_NN defenses_NNS [_NN 31_CD ]_NN (_( M_NNP ._. Melin_NNP ,_, H_NNP ._. Jarva_NNP ,_, S_NNP ._. Meri_NNP ,_, and_CC H_NNP ._. Käyhty_NNP ,_, unpublished_JJ data_NNS )_) ._. If_IN
        this_DT were_VBD the_DT case_NN ,_, then_RB one_PRP could_MD envision_VB that_IN certain_JJ capsular_NN types_NNS might_MD in_IN fact_NN
        follow_VBP a_DT different_JJ age-specific_JJ incidence_NN ._. In_IN particular_JJ ,_, recent_JJ analyses_NNS suggest_VBP that_IN
        serotypes_NNS 1_CD and_CC 5_CD have_VBP relatively_RB stable_JJ incidence_NN over_IN a_DT range_NN of_IN age_NN groups_NNS (_( W_NNP ._. P_NN ._.
        Hausdorff_NNP ,_, D_NNP ._. R_NN ._. Feikin_NNP ,_, and_CC K_NNP ._. P_NN ._. Klugman_NNP ,_, unpublished_JJ data_NNS )_) ._.
        The_DT evidence_NN adduced_JJ here_RB is_VBZ subject_JJ to_TO several_JJ limitations_NNS ._. With_IN respect_NN to_TO the_DT
        relative_JJ timing_NN of_IN acquisition_NN of_IN protection_NN against_IN different_JJ serotypes_NNS ,_, one_PRP could_MD
        postulate_NN that_IN because_IN some_DT of_IN the_DT most_RBS common_JJ pneumococcal_NN serotypes_NNS ,_, such_JJ as_IN 6_CD B_NNP ,_, 19_CD F_NN ,_, and_CC
        23_CD F_NN ,_, are_VBP also_RB among_IN the_DT least_JJS immunogenic_JJ [_NN 12_CD ]_NN ,_, the_DT effective_JJ exposure_NN of_IN the_DT immune_JJ system_NN
        is_VBZ more_RBR consistent_JJ across_IN serogroups_NNS than_IN it_PRP appears_VBZ from_IN serogroup_NN frequency_NN alone_RB ._.
        However_RB ,_, this_DT pattern_NN is_VBZ not_RB general_JJ ;_: for_IN example_NN ,_, serotype_NN 14_CD is_VBZ both_DT very_RB common_JJ and_CC
        highly_RB immunogenic_JJ [_NN 12_CD ]_NN ._. With_IN respect_NN to_TO the_DT absolute_JJ timing_NN of_IN protection_NN relative_JJ to_TO the_DT
        acquisition_NN of_IN antibody_NN ,_, one_PRP could_MD argue_VB that_IN low_JJ levels_NNS of_IN anticapsular_NN antibody_NN ,_, perhaps_RB
        of_IN low_JJ affinity_NN ,_, may_MD be_VB present_JJ and_CC even_RB active_JJ at_IN levels_NNS below_IN those_DT that_WDT can_MD be_VB reliably_RB
        detected_VBN by_IN current_JJ assays_NNS ,_, or_CC that_IN B_NNP cell_NN memory_NN may_MD be_VB present_JJ and_CC protective_JJ at_IN an_DT
        earlier_JJR age_NN than_IN that_DT at_IN which_WDT high_JJ levels_NNS of_IN antibody_NN are_VBP measurable_JJ ._. Inferences_NNP about_IN
        protective_JJ antibody_NN concentrations_NNS from_IN animal_NN studies_NNS and_CC from_IN concentrations_NNS achieved_VBN by_IN
        vaccines_NNS suffer_VBP from_IN several_JJ uncertainties_NNS ._. Making_VBG allowances_NNS for_IN all_DT of_IN these_DT limitations_NNS ,_,
        we_PRP nonetheless_RB believe_VBP the_DT data_NNS suggest_VBP that_WDT mechanisms_NNS other_JJ than_IN anticapsular_NN antibody_NN
        are_VBP primarily_RB responsible_JJ for_IN the_DT age-specific_JJ decline_NN in_IN pneumococcal_NN invasive_JJ disease_NN
        that_WDT starts_VBZ at_IN the_DT age_NN of_IN 1_CD y_NN ._.
        The_DT likelihood_NN that_WDT mechanisms_NNS other_JJ than_IN anticapsular_NN antibody_NN confer_VB immunity_NN to_TO
        pneumococcal_NN disease_NN has_VBZ important_JJ implications_NNS with_IN respect_NN to_TO vaccine_NN design_NN ._. As_IN
        experience_NN with_IN conjugate_NN pneumococcal_NN vaccines_NNS in_IN children_NNS unfolds_VBZ ,_, it_PRP is_VBZ becoming_VBG
        increasingly_RB clear_JJ that_IN such_JJ a_DT strategy_NN suffers_VBZ from_IN several_JJ limitations_NNS ,_, including_VBG the_DT
        possibility_NN of_IN serotype_NN replacement_NN (_( already_RB confirmed_VBD in_IN several_JJ clinical_JJ trials_NNS )_) ,_, a_DT
        modest_JJ effect_NN on_IN nasopharyngeal_NN colonization_NN ,_, limited_JJ serotype_NN coverage_NN ,_, cost_NN ,_, and_CC
        difficulties_NNS in_IN production_NN that_WDT have_VBP led_VBN to_TO shortages_NNS since_IN licensure_NN ._. A_DT better_JJR
        understanding_NN of_IN the_DT mechanisms_NNS that_WDT underlie_VB natural_JJ immunity_NN to_TO pneumococcus_JJ could_MD pave_VB
        the_DT way_NN for_IN the_DT development_NN of_IN more_JJR effective_JJ ,_, species-specific_JJ pneumococcal_NN vaccines_NNS ._.
      
    
  
